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Background. Brain regions subserving emotion have mostly been studied using functional magnetic resonance imaging (fMRI)
during emotion provocation procedures in healthy participants. Objective. To identify neuroanatomical regions associated with
spontaneous changes in emotional state over time. Methods. Self-rated emotional valence and arousal scores, and regional
cerebral blood ﬂow (rCBF) measured by perfusion MRI, were measured 4 or 8 times spanning at least 2 weeks in each of 21
subjects with Parkinson’s disease (PD). A random-eﬀects SPM analysis, corrected for multiple comparisons, identiﬁed signiﬁcant
clusters of contiguous voxels in which rCBF varied with valence or arousal. Results. Emotional valence correlated positively
with rCBF in several brain regions, including medial globus pallidus, orbital prefrontal cortex (PFC), and white matter near
putamen, thalamus, insula, and medial PFC. Valence correlated negatively with rCBF in striatum, subgenual cingulate cortex,
ventrolateral PFC, and precuneus—posterior cingulate cortex (PCC). Arousal correlated positively with rCBF in clusters including
claustrum-thalamus-ventral striatum and inferior parietal lobule and correlated negatively in clusters including posterior insula—
mediodorsal thalamus and midbrain. Conclusion. This study demonstrates that the temporal stability of perfusion MRI allows
within-subject investigations of spontaneous ﬂuctuations in mental state, such as mood, over relatively long-time intervals.
1.Background
Even though Parkinson’s disease (PD) is a neurodegenerative
disease deﬁned by motor features [1], psychiatric sequelae
are common such as depression, anxiety, and apathy [2, 3].
Previousstudieshaveshownalterationofemotionalprocess-
ing in PD including reduced emotional physiologic response
[4], impaired emotional word recognition [5], and impaired
arousal judgment but normal valence [6]. The bulk of the
evidence suggests that these changes result primarily from
thedegenerativeprocessinthebrain,andarenotmerelypsy-
chological reactions to disability [3]. Pathologically, Braak
and Del Tredici [7] found that in PD clinical stages 1–3
(stage 4-5 pathologically), neurodegeneration could be seen
in almost all areas of the brain including prefrontal cortex
(PFC) and limbic system. Brain areas aﬀected by PD that
are hypothesized to cause emotional dysfunction including
raphe nuclei, locus ceruleus, amygdala, mesolimbic, meso-
cortical, mesothalamic dopaminergic systems, and cingulate
cortex [8]. Furthermore, neuroimaging studies have shown
that a decrease in dopamine transporter availability in left
putamen was associated with a reduction of ventrolateral
prefrontal cortex activity during emotional gesture recog-
nition tasks [9]. Lack of amygdala activation was observed
by visual event-related potentials (ERPs) during facial
expression recognition [4]. Based on these data, emotional
processing in PD may diﬀer from that of healthy controls.
Most fMRI experiments on emotional processing used
a variety of validated aﬀective stimuli to elicit changes in
mood; stimuli included pictures [10], sounds [11], and
words [12]. These studies have identiﬁed various brain
regions involved in the emotional responses to these stimuli,2 Parkinson’s Disease
depending partly upon the type of stimulus [13, 14].
However, studies designed in this manner may identify brain
regions involved in aﬀective perception or naming rather
than those that produce internal emotional states. Alter-
natively, the emotional states transiently induced by these
artiﬁcial stimuli may be pale shadows of the emotional states
peopleexperienceinresponsetospontaneousthoughts,real-
life events, idiopathic mood disorders, or the cellular and
pharmacological pathology of PD.
We studied self-rated emotional valence and arousal in
patients with PD on several occasions per subject, without
attempting to induce speciﬁc emotional states. These
patients were participating in a pharmacological perfusion
MRI study of an adenosine A2a receptor antagonist and
the dopamine precursor levodopa, but emotional ratings
were obtained in the same drug and placebo conditions in
each subject, allowing us to separate the eﬀects of drug from
spontaneous variance in emotional state across participants.
The objective was to describe brain areas associated with
naturalistic emotional state in PD. We hypothesized that
spontaneous variation in self-rated emotional state would
be accompanied by statistically signiﬁcant changes in brain
activity, as indexed by regional cerebral blood ﬂow (rCBF)
measured with perfusion MRI.
2.MaterialsandMethods
These data were collected during the course of a Phase
IIa clinical and brain imaging study of the investigational
adenosine A2a receptor antagonist SYN115, and the primary
analyses of those data are reported elsewhere [15, 16]. The
results presented here have not been previously reported
except in abstract form [17].
2.1. Regulatory Approvals, Registrations, and Patient Consents.
This study was approved by the Washington University
Human Research Protection Oﬃce. Written documentation
of informed consent was obtained in advance from each
subject. Levodopa and SYN115 were given under US FDA
Investigational New Drug application (IND) number 78,230.
2.2. Study Participants. Further details appear in Black et al.
[15].Brieﬂy,21patientswithParkinson’sdisease(Hoehnand
Yahrstages1–3)onastabledoseoflevodopafor30dayswere
studied. Exclusion criteria included cognitive impairment
indicated either by MMSE score <23 or estimated premorbid
IQ <70 [18, 19], neurological diseases other than PD, self-
reported history of psychosis or mania, current depression
indicated by Geriatric Depression Scale Short Form [20]
score >7, or current use of a dopamine agonist. All were
Caucasian and right-handed, and 13 were male. Mean age
was 60.8 years (range 44–73 years), mean duration of PD
symptoms was 5.3 years (range 0.9–10.8 years), mean “oﬀ”
U P D R S( p l a c e b od a y ,b e f o r el e v o d o p a )w a s2 2 . 5( r a n g e7 –
51),andhalfhadeverexperienceddopa-induceddyskinesias.
2.3. Study Protocol. Participants were randomly assigned
either (a) to take SYN115 twice daily for a week, wait 1
week (washout period), then take a matching placebo twice
daily for a week, or (b) the reverse order. For 14 participants,
eachdoseofactivedrugcontained60mgofSYN115,whereas
12 subsequent subjects (5 of whom had participated in
the 60mg placebo study) received 20mg at each dose.
Participants and staﬀ were blind to assignment.
On the last day of each treatment week, participants
abstained from food, caﬀeine, and antiparkinsonian medica-
tion overnight, but took the last dose of SYN115 or placebo
at 6am at home. At the imaging center, they took 200mg
carbidopa, and then underwent a set of clinical and MRI
assessments. An intravenous levodopa infusion was then
begun, dosed in such a way as to rapidly produce and then
maintain a steady plasma concentration [21], with a target
concentration of 600ng/mL. At least 25 minutes after the
levodopa infusion started, all MRI and clinical assessments
were repeated while the levodopa infusion continued.
Participants rated their emotional state in each of four
conditions: (1) before and (2) during levodopa infusion
(after carbidopa) while taking oral SYN115, and (3) before
and (4) during levodopa infusion while taking placebo pills.
In each of these 4 conditions, 8 perfusion MRI (CBF) scans
were acquired. In 4 of the 8 scans in each condition, the
participant ﬁxated on a crosshair throughout the entire 2.73
minutes of each scan; half of these were white on black and
halfwereblackonwhite.In2scans,an8Hzreversingcircular
checkerboard pattern surrounded the ﬁxation crosshair, and
in 2 scans the participant performed a 2-back letter working
memory task for the entire scan.
2.4. Visual Analog Scale (VAS) and Scoring of Emotional
Valence and Arousal. The circumplex model of emotion [22]
describes human emotional states in terms of two inde-
pendent constructs called valence and arousal (also called
valenceand“activation,”atermavoidedhereduetopotential
confusion with the homonymous word as used in the
neuroimaging literature). The original model suggests but
does not specify a numerical coordinate system for valence
and arousal scores. For this study they were computed
as follows. Participants rated various antipodal pairs of
emotional descriptors from the circumplex model using
VAS [23] displayed on a computer. They were instructed
to freely self-evaluate their current feelings by clicking on
the scale for each pair of emotional descriptors. The VAS
ratings were recorded on 100mm scales with anchor terms
chosen from the original item set for 4 categories, that is,
(a) negative valence, neutral arousal versus positive valence,
neutral arousal (sad-happy, grouchy-cheerful); (b) negative
valence, high arousal versus positive valence, low arousal
(nervous-calm, distressed-relaxed); (c) negative valence, low
arousal versus positive valence, high arousal (sluggish-lively,
dull-excited); (d) neutral valence, high arousal versus neutral
valence, low arousal (intense-tranquil, aroused-passive). For
each VAS, the left item anchor was scored as 0 and the right
anchor as 100. Subjects were advised to use the full 100mm
VAS range for each item and to score how they felt “at this
moment.” Valence and arousal scores were computed from
the VAS-item scores by the following formulae:Parkinson’s Disease 3
(1) valence score = [average (a, b, c)/50]−1; possible
range −1t o+ 1 ;
(2) arousal score = 1−[average (b, 100−c, d)/50]; possi-
ble range −1t o+ 1 .
2.5. MRI Methods. All MRI data were acquired on the
Siemens 3T Tim Trio with matrix head coil. ASL images
were acquired with the commercial Siemens pulsed arterial
spin labeling (pASL) sequence [24]; the center-to-center
slice distance was 7.5mm. Details of image acquisition and
transformation to scaled CBF images in atlas space are given
elsewhere [15].
2.6. Statistical Analysis. Only those voxels were analyzed,
that were represented in every EPI image in every sub-
ject. Statistical analysis of the CBF data was done via
a two-level, random eﬀects model using SPM8 software
(http://www.ﬁl.ion.ucl.ac.uk/spm/). First, a voxelwise gen-
eral linear model (GLM) was computed for each subject.
This ﬁrst-level GLM followed the method of Henson and
Penny [25] by including factors coding for each of the
16 possible combinations of drug (SYN115 or placebo),
levodopa (before versus during infusion), and task (the 4
behavioral conditions described in Study Protocol, above).
The GLM also included 3 covariates, representing the
pertinent valence and arousal scores and their interaction.
This approach partitions the variance from each subject’s
CBF data at a given voxel into components representing
valence, arousal, and their interaction, plus components
representing the nuisance variables drug, levodopa, task, and
all their interactions. The β (model coeﬃcient) images from
each subject for the valence and arousal covariates became
the input data for the ﬁnal, second-level analysis.
The second-level (across-subjects) analysis was a voxel-
wise general linear model (GLM) that tested whether, across
subjects, the mean β value for valence was signiﬁcantly
greater than zero, after controlling for sex, age, and dose
group (60 versus 20mg SYN115 b.i.d. during the active drug
week). A corresponding analysis tested whether mean β was
signiﬁcantly less than 0. The same analyses were done for
arousal. Multiple-comparisons correction was performed at
the cluster level with the false discovery rate (FDR) set at
P = 0.05. Approximate anatomical locations were provided
by the Talairach Daemon client (http://www.talairach.org)
[26], with corrections by reference to the study-speciﬁc MRI
template atlas image.
3. Results
3.1. Valence and Arousal, and Their Association with Subject
Characteristics. The mean value for each VAS item and for
the emotional valence and arousal scores are given in Table 1
and depicted on a diagram of the circumplex model of
emotion (Figure 1). Across conditions, participants tended
tohavepositivevalence,mean0.375±0.339,andlowarousal,
mean −0.199 ± 0.254 (in other words, they tended to be
closer to cheerful and calm than to the opposite). Valence
and arousal scores correlated negatively with each other
Table 1: Visual analog scale scores for each emotion item pair.
Visual analog scale Mean, mm (range)
(1) Sad-happy 72.721 (8–100)
(2) Grouch-cheerful 77.471 (19–100)
(3) Nervous-calm 72.000 (5–100)
(4) Distressed-relaxed 74.731 (11–100)
(5) Sluggish-lively 55.010 (7–100)
(6) Dull-excited 60.529 (23–96)
(7) Intense-tranquil 67.375 (0–100)
(8) Aroused-passive 61.038 (1–100)
Valence score 0.375 (−0.333 to 0.967), SD 0.339
Arousal score −0.199 (−0.673 to 0.423), SD 0.254
(r =− 0.31, P<. 01); that is, subjects who were less aroused
(more tranquil) tended also to be happier.
Table 2 shows associations of valence and arousal with
pharmacological status and demographic variables. SYN115
increased valence (t(25) = 2.57, P = 0.02) and valence
decreased from before to on levodopa (t(25) =− 2.26, P =
0.03), though the mean change in valence score with either
drug was less than 5% of the available range. Demographic
variables and PD factors were not signiﬁcantly associated
with emotional valence or arousal (Table 2).
3.2. Perfusion MRI Data
3.2.1. Correlations of rCBF with Valence. Random-eﬀects
analysis revealed signiﬁcant positive correlations of rCBF
with valence across subjects. We found signiﬁcant areas in
prefrontal-subcortical circuits; that is, bilateral dorsolateral
PFC, bilateral anterior cingulate cortices (ACCs), orbital
frontal cortex, striatum, and thalamus. Other signiﬁcant
clusters were observed in cortical areas including left and
right ventral frontotemporal regions, lateral parietal cortex,
insula, right motor, and premotor areas (see Table 3(a) and
Figures 2(a)–2(c).
Areas whose rCBF correlated negatively with valence
included a part of ACC, bilateral subcallosal cingulate cortex
(SCC), along with parts of caudate and putamen, bilateral
inferior frontal gyri, bilateral superior parietal lobule (SPL),
inferior parietal lobule, precuneus, and PCC (see Table 3(b)
and Figures 2(d)–2(f)).
3.2.2. Correlations of rCBF with Arousal. Random-eﬀects
analysis of rCBF-arousal correlations found no voxels whose
t value exceeded our predetermined voxel-level threshold
corresponding to uncorrected P = 0.001. However, as an
exploratory analysis, relaxing that initial threshold to a value
corresponding to uncorrected P = 0.005 revealed several
clusters that were signiﬁcant after correction for multiple
comparisons (Table 4 and Figures 3(a)-3(b)).
3.2.3. Correlations of rCBF with the Interaction of Valence and
Arousal. Ar a n d o m - e ﬀects analysis of the valence × arousal
interactionfoundnoactivatedclusterssigniﬁcant atP<0.05
after correction for multiple comparisons.4 Parkinson’s Disease
Table 2: Associations of valence and arousal with pharmacological status and demographic variables.
Valence Arousal P (valence) P (arousal) N†
Eﬀect of SYN115 (mean diﬀerence [unitless]) +0.08 +0.05 0.02∗ 0.08 26
On levodopa minus pre-levodopa (mean diﬀerence [unitless]) −0.06 −0.04 0.03∗ 0.18 26
Age (correlation, r) 0.09 0.18 0.70 0.43 21
Hoehn and Yahr stage (correlation, r)0 . 2 2 −0.03 0.34 0.89 21
UPDRS (correlation, r) 0.08 0.08 0.42 0.41 104
Sex (t-test) 0.82 0.92
Male (mean) 0.33 −0.22 13
Female (mean) 0.30 −0.20 8
PD symptoms worse on which side of body? (t-test) 0.25 0.34
Right (mean) 0.26 −0.17 13
Left (mean) 0.43 −0.28 7‡
∗P ≤ 0.05.
†21 people, 26 experiments (5 people participated twice, once for the 20mg b.i.d. study, once for the 60mg b.i.d. study), 4 UPDRS measurements per
experiment (26 ×4 = 104).
‡One subject was equally aﬀected on left and right and was excluded from this analysis.
Table 3 :C B Fc o r r e l a t e sw i t he m o t i o n a lv a l e n c e .
( a )C l u s t e r si nt h eb r a i ni nw h i c hC B Fc o r r e l a t e sp o s i t i v e l yw i t hv a l e n c e
FDR-corrected
P value
Number of
voxelsa
Peak T value
(22d.f.)
Coordinates of
peak T value Side of brain Anatomical description of cluster
<10−15 674 3.86 28.5, 21, 18 Right Middle frontal gyrus (BA 8, 9), precentral gyrus, anterior
cingulate (BA 32), insula, putamen, caudate
0.001 76 3.86 4.5, 57, 18 Bilateral Medial and superior frontal gyri (BA 10, 9)
0.001 97 3.86 −58.5, 3, 21 Left Precentral gyrus (BA 6)
0.002 87 3.86 16.5, −3, −3 Right Medial globus pallidus, ventrolateral thalamus, amygdala,
frontal prepiriform cortex ventral to accumbens
0.002 82 3.86 −16.5, 6, −18 Left
Olfactory area, parahippocampal gyrus, medial globus
pallidus/thalamus border, thalamus, hypothalamus,
substantia nigra
0.053 36 3.85 28.5, 42, −9 Right Middle frontal gyrus (BA 11)
0.010 56 3.84 −46.5, −60, 33 Left Angular gyrus and inferior parietal lobule (BA 39, 40)
aEach voxel contained 0.027mL.
(b) Clusters in the brain in which CBF correlates negatively with valence
FDR-corrected
P value
Number of
voxels
Peak T value
(22d.f.)
Coordinates of
peak T value Side of brain Anatomical description of cluster
<0.0002 117 3.86 −34.5, −42, 66 Left
Superior parietal lobule and precuneus (BA 7),
postcentral gyrus (BA 5), posterior cingulate cortex
(BA 31)
<10−5 178 3.86 −13.5, 12, 3 Bilateral Subcallosal gyrus (BA 25), left caudate and putamen
0.007 67 3.86 4.5, −75, 54 Right Superior parietal lobule and precuneus (BA 7),
postcentral gyrus (BA 5)
0.020 46 3.86 −34.5, −15, 57 Left Precentral gyrus (BA 6), postcentral gyrus (BA 3)
0.014 54 3.86 43.5, −39, 63 Right Inferior parietal lobule (BA 40), superior parietal lobule
(BA 7), postcentral gyrus (BA 5)
0.008 63 3.85 43.5, 39, −6 Right Inferior frontal gyrus (BA 47)—lateral frontal part
0.020 46 3.85 25.5, −63, 6 Right Lingual gyrus (BA 18, 19)
0.036 39 3.85 −37.5, 33, −6 Left Inferior frontal gyrus (BA 47)
0.043 36 3.83 25.5, 24, −6 Right Inferior frontal gyrus (BA 47)
Note: Only clusters signiﬁcant after correction for multiple comparisons are shown here.Parkinson’s Disease 5
Aroused, intense (0)
(0) Distressed, nervous Excited, lively (100)
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Tranquil, passive (100)
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High arousal
Low arousal
57.77; SD 22.46
73.37; SD 23.76
64.21; SD 23.32
Figure 1: Score of visual analog scale on circumplex model of emotion. The 4 diameters shown represent the 8 pairs of adjectives used for
the VAS items that generated the valence and arousal scores. The short perpendicular mark on each diameter represents the mean value for
the corresponding VAS items in this sample.
Table 4: CBF correlates with emotional arousal.
(a) Clusters in the brain in which CBF correlates positively with emotional arousal†
FDR-corrected
P value
Number of
voxels
Peak T value
(22d.f.)
Coordinates of
peak T value Side of brain Anatomical description of cluster
0.039 84 3.00 31.5, −9, −6 Right Putamen, thalamus (ventrolateral), hippocampus
0.039 85 3.00 −34.5, −75, 6 Left Middle temporal gyrus (BA 39), middle occipital
gyrus (BA 19)
<0.0005 231 3.00 −37.5, −57, 45 Left Inferior parietal lobule (BA 40), superior occipital
gyrus (BA 19)
0.039 100 3.00 34.5, −57, 39 Right Inferior parietal lobule (BA 40), superior parietal
lobule and precuneus (BA 7)
(b) Clusters in the brain in which CBF correlates negatively with emotional arousal†
FDR-corrected
P value
Number of
voxels
Peak T value
(22d.f.)
Coordinates of
peak T value Side of brain Anatomical description of cluster
0.001 216 3.00 −34.5, −27, 27 Left Striatum and nearby white matter, thalamus
(medial dorsal), insula (BA 13)
0.015 110 3.00 −34.5, −60, 57 Left Precuneus and superior parietal lobule (BA 7)
0.005 139 3.00 −25.5, −6, −9L e f t
Putamen, claustrum, insula (BA 13),
amygdala-striatal transition area, superior
temporal gyrus (BA 22, 38), inferior frontal gyrus
(BA 47)—ventral frontal part
<10−7 577 3.00 13.5, −45, −6 Right
Superior and middle occipital gyrus, cuneus (BA
17, 18, 19), posterior cingulate cortex (BA 23),
thalamus (medial dorsal), midbrain (central
portion and red nucleus)
0.005 149 3.00 34.5, −81, 39 Right Superior parietal lobule and precuneus (BA 7)
†No voxels passed the predeﬁned voxel-level threshold of P<0.001. For hypothesis generation, we repeated our analysis using a voxel-level threshold of P<
0.005, and those results are shown here.
Note: only clusters signiﬁcant after correction for multiple comparisons are shown here.6 Parkinson’s Disease
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Figure 2: Statistical parametric (T) maps for correlations with valence. (a–c) Positive correlation with valence in (a) right putamen (22.5,
15, 6); (b) right medial globus pallidus (16.5, −3, −3); (c) right middle frontal gyrus (28.5, 42, −9) (BA 11). (d–f) Negative correlation with
valence in (d) right subcallosal gyrus (4.5, 24, −15) (BA25); (e) left caudate (−13.5, 12, 3); (f) right inferior frontal gyrus (38, 27, 0) (BA47).
4. Discussion
This study found a number of brain regions whose activity
increased or decreased with changes in self-rated current
mood state.Emotional stateratings,drewonthefacevalidity
and experimental history of the circumplex model of emo-
tion [22], augmented here by a numerical implementation
of the valence and arousal constructs. The conservative
statistical approach employed for this analysis lends credence
to the results and uses general linear modeling to minimize
the potential confounds of demographic variation (age and
sex) and unrelated experimental manipulations (such as
medication status). Additionally, the study design allowed us
to study ecologically valid or “real,” that is, spontaneouslyParkinson’s Disease 7
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Figure 3: Statistical parametric (T) maps for correlations with arousal. (a) Positive correlation with arousal in right putamen (28.5, 6, 0).
(b) Negative correlation with arousal in left amygdala-striatal transition area (−25.5, −6, −9).
experienced, internal emotional state, which may more
faithfully reﬂect patients’ day-to-day experiences.
Ontheotherhand,thestudyhasanumberoflimitations,
most of which derive from the fact that correlation of rCBF
with current emotional state was not a primary goal of
the data collection. Mood ratings were not done within
the scanning session itself, but rather within a half hour
or so, under broadly similar physiological conditions. This
may have added noise to our results, so that we may have
failed to detect some true correlations. Second, valence and
arousal scores were (inversely) correlated, interpretation of
results related to one emotional dimension might also be
a result of changes in the other. However, the inclusion
in our SPM model of a valence-arousal interaction should
help disentangle their relation to rCBF. The correlation also
tends to restrict the range of emotional states sampled. For
that and perhaps other reasons, the range of emotional
states reported by the subjects in our data did not equally
sample all quadrants of emotional experience. Speciﬁcally,
there was a bias of positive over negative valence, and low
over high arousal. As a consequence, negative correlations
with valence came primarily from data with positive values.
Additionally, we cannot comment conclusively on whether
regions identiﬁed as correlating with self-rated mood in this
study are speciﬁc to PD, since we did not include healthy
control subjects.
4.1. Nonimaging Results. Emotional rating in our partic-
ipants tended towards positive valence and low arousal
(Table 1,Figure 1).Wedidnottestwhetherthisdiﬀeredfrom
a control group. However, Drago et al. [6] show that non-
demented PD patients under-rate arousal in others’ facial
expressions, compared to healthy control subjects, and that
their spatial judgments are less aﬀected than controls’ by
emotional stimuli. Imaging studies have shown decreased
activationofemotionalregionstoemotionalfacesorgestures
[9]. These ﬁndings may correspond to observations that PD
patients actually experience lower emotional arousal, along
with other manifestations of apathy [3, 4].
The slight improvement in mood with SYN115 is not
surprisinggiventhatitisanadenosine2aantagonist(caﬀeine
is a nonspeciﬁc adenosine antagonist). The small decrease in
valence on levodopa may seem counterintuitive, depression
and anxiety commonly attend wearing oﬀ of individual
levodopa doses in PD [27]. However, on-levodopa data were
always collected a few hours after the oﬀ-levodopa data, and
if subjects were merely less enthusiastic later in the study
day, as one might expect, then valence and arousal would be
lower, causing an apparent association with levodopa.
ThelackofcorrelationofUPDRSwithmoodratingsmay
beaTypeIIerror,butisconsistentwithotherdatasuggesting
that, contrary to common expectation, motor impairment is
at best a modest predictor of mood state in PD [3].
4.2. Regions Associated with General Emotional Processing.
Our study revealed a number of neural substrates associ-
ated with naturalistic emotional state; that is, (a) medial
frontal PFC/ACC—subcortical circuit—medial PFC/ACC,
basal ganglia, and thalamus; (b) limbic and paralimbic—
amygdala, hippocampus and parahippocampal gyrus, thala-
mus, mamillary body, and PCC, insula, parietal, and lateral
PFC;(c)visualsystem—occipitalandtemporalcortex.These
regions are generally in line with previous studies in healthy
controls.
In a meta-analysis of functional neuroimaging studies
of human emotions by Phan et al. [28, 29], medial frontal
PFC (BA 9, 10) was activated in response to nonspeciﬁc
emotion. In other words, this region was involved in emo-
tional processing regardless of valence, arousal, or induction
method. In the present study, we found some brain regions
that contained activations associated with either arousal or
valence, such as basal ganglia (BG), thalamus, and parietal
lobe. Basal ganglia were correlated with happiness induction
in 70% of the studies, and disgust induction in 60% [28]
as well as responded to arousal stimuli evidenced by fMRI
and skin conductance response (SCR) [30]. The thalamus is
connected to BG, ACC, medial frontal PFC, orbital PFC, and
dorsolateral PFC, forming several frontal-subcortical circuits8 Parkinson’s Disease
[31]. The ACC is also closely interconnected to medial
PFC. Lesions in the anterior cingulate—subcortical circuit
can produce apathy [31], and the apathy experienced by
PD patients who undergo subthalamic (STN)—deep brain
stimulation (DBS) has been attributed to dysfunction of
medial PFC [32, 33]. In addition, the thalamus links other
structures in the limbic system, which is responsible for
fundamental instinctive behaviors, cognition, and emotion,
by receiving input from amygdala, basal forebrain, cere-
bellum, hippocampus, and septal nuclei, and projecting to
prefrontal, cingulate, and parietal cortex [34]. Therefore, the
BG, thalamus, and parietal cortex might be related to general
emotion processing as a part of this network.
4.3. Associations between Valence and rCBF. We found re-
gions in limbic and paralimbic structures—amygdala,
medial PFC/rostral ACC, lateral PFC, and insula—that were
positively correlated with valence; whereas subcallosal and
posterior cingulate cortex (SCC and PCC) were negatively
correlated with valence.
4.3.1. Positive Correlation with Valence. Amygdala responses
to valence or arousal stimuli have varied. Although amygdala
response was related to arousal stimuli [35], and over 60%
of studies reported amygdala activation in response to fear
induction [28, 29], other studies have found activation
to happy faces [36] or have linked amygdala activity to
both valence and arousal [37, 38]. Thus, it may respond
to salient characteristics of emotion. However, we found
amygdala rCBF positively related only to valence. According
totheneuropathologicalstagingofPD(stages1–6)proposed
by Braak and colleagues [39], amygdala dysfunction ﬁrst
a p p e a r si np r e s y m p t o m a t i cs t a g e3i nap a r t i c u l a rr e g i o n .
In addition, dopamine is lost in the amygdala due to
degeneration of the ventral tegmental area in PD. In fact,
loss of dopaminergic innervation of amygdala and other
limbic structures were observed in PD subjects diagnosed
with major depression [40], and dopamine modulates the
response of amygdala to fearful stimuli in PD patients with
depression [41].
The ACC is known to be involved in a form of attention
that serves to regulate both cognitive (dorsal) and emotional
(ventral) processings [42]. Valence perception has been
reported to be normal in nondemented and nondepressed
PD patients [6], thus, the activity in medial frontal PFC
mightreﬂectactivationofcircuitsinvolvedinvalence-related
attention or decision making.
4.3.2. Negative Correlation with Valence. Subcallosal cin-
gulate cortex was associated with sadness in about 46%
studies [29], in line with our results. Clinically, patients with
more than 3 episodes of untreated MDD had smaller SCC
volume than controls [43, 44], and DBS of SCC may beneﬁt
treatment resistant depression [45].
Posterior cingulate cortex was also negatively correlated
with valence. PCC has been linked to emotional processing
and is thought to enhance memory for emotional stimuli
[46]. A study that controlled for nonemotional, memory
enhancing stimulus features suggested that this region might
mediate interactions of emotional and memory-related
processes [47]. Activity in PCC has also been reported
to correlate with severity of anxiety symptoms in major
depression and obsessive-compulsive disorder [48, 49]a n d
wasassociatedwithlevodopadose-relatedmoodﬂuctuations
in PD patients [50].
4.4. Associations between Arousal and rCBF. We adopted a
more permissive ﬁrst-stage threshold to ﬁnd any regions
in which rCBF correlated with emotional arousal. The
approach is reasonable, but as this threshold diﬀers from
the prespeciﬁed methods, the arousal results should be taken
with a grain of salt.
The rCBF in hippocampus and middle temporal gyrus
correlated positively with arousal in the present study,
consistentwiththestudyofNielenetal.[51].Theconnection
with hippocampus may relate to observations that arousal
can modulate memory [52].
Results from prior studies were arguable whether occip-
ital lobes actually responded to valence or to arousal. The
studies of Mour˜ ao-Miranda et al. [53] and Lane et al. [54]
found that visual processing could vary with either valence
or arousal, consistent with our ﬁndings, in which lingual
gyrus was also associated negatively with valence, whereas
others found occipital activation only when participants
were presented stimuli of negative valence [51, 55]. The
activation of the visual system with emotional valence and
arousal may be that both can increase attentional processing.
Emotional and attentional processings both involve medial
frontalPFC,andavarietyoffunctionalneuroimagingstudies
have suggested that attention modulates activity of extra-
striate visual cortex [55]. Moreover, threat stimuli lead to
increased perceptual processing [56]. Our data might extend
prior knowledge that current internal emotion, and not just
visually presented emotional stimuli, may enhance visual
system activity.
5. Conclusion
Emotions are usually regarded as brief but intense responses
to changes in the environment featuring a number of
subcomponents: (a) cognitive appraisal, (b) subjective feel-
ing, (c) physiological response, (d) expression, (e) action
tendency, and (f) regulation [57]. In addition, emotional
stimulation can be of an interoceptive or exteroceptive
nature. Diﬀerent methods used to provoke emotional state
changescanactivatediﬀerentsystems.Forexample,therecall
method activated mostly ACC and insula, whereas amygdala
and occipital lobe were activated by visual induction [28].
Many neuroimaging studies of emotion in healthy vol-
unteers have used clever methods to transiently stimulate
emotional perception or attempt to quickly induce a given
emotional state. Some experimental designs were chosen in
part due to the limitations of blood oxygen level dependent
(BOLD) fMRI, namely, its nonquantitative nature and the
marked decline in signal-to-noise ratio of BOLD signal at
time intervals greater than a few minutes.Parkinson’s Disease 9
The use of ASL perfusion fMRI enabled us to study
within-subject ﬂuctuations of internal mood states over
relatively long periods of time (hours to weeks), a study
design that is not possible with BOLD fMRI. Since we
studied self-perceived emotional state without intentional
provocation of a speciﬁc emotion, we could examine the
eﬀect of “subjective feeling” while being minimally con-
founded by other emotional processes. Furthermore, the
rated emotion might be as a result of both “interoceptive”
and “exteroceptive” natural stimulation that might result
in stronger and more regions emotional stimulation, as
compared to only one induction method alone. Despite the
limitations of this study, it may demonstrate the potential
utility of perfusion fMRI in the study of emotion.
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